Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Treatment With Atomoxetine Hydrochloride in Child and Adolescents With Attention-Deficit/Hyperactivity Disorder and Comorbid Dyslexia

NCT00191048 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00191048
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00191048 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Treatment With Atomoxetine Hydrochloride in Child and Adolescents With Attention-Deficit/Hyperactivity Disorder and Comorbid Dyslexia
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2003
Completion date
March 31, 2006
Enrollment
105
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

attention-deficit/hyperactivity disorder, comorbid dyslexia